Treatment of invasive fungal disease using anidulafungin alone or in combination for hematologic patients with concomitant hepatic or renal impairment

被引：7

作者：

Montesinos, Pau ^{[1
]}

Rodriguez-Veiga, Rebeca ^{[1
]}

Martinez-Cuadron, David ^{[1
]}

Boluda, Blanca ^{[1
]}

Navarro, Ines ^{[1
]}

Vera, Belen ^{[1
]}

Alonso, Carmen M. ^{[1
]}

Sanz, Jaime ^{[1
]}

Lopez-Chulia, Francisca ^{[1
]}

Martin, Guillermo ^{[1
]}

Jannone, Rosa ^{[2
]}

Sanz, Guillermo ^{[1
]}

Lancharro, Aima ^{[1
]}

Cano, Isabel ^{[1
]}

Palau, Javier ^{[1
]}

Lorenzo, Ignacio ^{[1
]}

Jarque, Isidro ^{[1
]}

Salavert, Miguel ^{[3
]}

Ramirez, Paula ^{[2
]}

Angel Sanz, Miguel ^{[1
]}

机构：

[1] Hosp Univ La Fe, Dept Hematol, Valencia, Spain

[2] Hosp Univ La Fe, Intens Care Unit Dept, Valencia, Spain

[3] Hosp Univ La Fe, Infect Dis Unit, Valencia, Spain

来源：

REVISTA IBEROAMERICANA DE MICOLOGIA | 2015年 / 32卷 / 03期

关键词：

Anidulafungin; Hematologic malignancies; High-risk; Invasive fungal disease; ASPERGILLOSIS; THERAPY;

D O I：

10.1016/j.riam.2014.10.003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Background: Invasive fungal disease (IFD) treatment is challenging in hematologic patients due to drug interactions and toxicities that limit the use of the antifungal agents. Aims: To analyze retrospectively in terms of safety and potential efficacy anidulafungin therapy, alone or in combination. Methods: Our institutional guidelines recommended anidulafungin treatment in hematologic patients with suspected IFD and concomitant renal or liver impairment (to avoid drug interactions and preserve organ function). Results: From 2008 to 2013,24 episodes of IFD occurring in 21 patients were classified as proven (4 cases), probable (15 cases) and possible (5 cases). Anidulafungin was administered alone (13%) or in combination (88%). Eight (33%) episodes were resolved, using monotherapy (1 out of 3, 33%) or a combined therapy (7 out of 21,33%). Twelve cases (50%) were registered as failure (death due to IFD progression in 4 patients, and treatment change due to lack of efficacy in 8), and 4 cases (17%) were not evaluable (death unrelated to the IFD). Anidulafungin was not withdrawn in any case due to toxicity. Conclusions: Anidulafungin therapy, alone or in combination, could be considered in hematologic patients with IFD and concomitant liver or renal impairment. Due to the low number of patients, we cannot draw any conclusion about efficacy. (C) 2014 Revista Iberoamericana de Micologia. Published by Elsevier Espana, S.L.U. All rights reserved.

引用

页码：185 / 189

页数：5

共 9 条

[1] Early clinical experience with anidulafungin at a large tertiary care medical center [J].

Brielmaier, Benjamin D. ;

Casabar, Ed ;

Kurtzeborn, Christine M. ;

McKinnon, Peggy S. ;

Ritchie, David J. .

PHARMACOTHERAPY, 2008, 28 (01) :64-73

[2] Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].

De Pauw, Ben ;

Walsh, Thomas J. ;

Donnelly, J. Peter ;

Stevens, David A. ;

Edwards, John E. ;

Calandra, Thierry ;

Pappas, Peter G. ;

Maertens, Johan ;

Lortholary, Olivier ;

Kauffman, Carol A. ;

Denning, David W. ;

Patterson, Thomas F. ;

Maschmeyer, Georg ;

Bille, Jacques ;

Dismukes, William E. ;

Herbrecht, Raoul ;

Hope, William W. ;

Kibbler, Christopher C. ;

Kullberg, Bart Jan ;

Marr, Kieren A. ;

Munoz, Patricia ;

Odds, Frank C. ;

Perfect, John R. ;

Restrepo, Angela ;

Ruhnke, Markus ;

Segal, Brahm H. ;

Sobel, Jack D. ;

Sorrell, Tania C. ;

Viscoli, Claudio ;

Wingard, John R. ;

Zaoutis, Theoklis ;

Bennett, John E. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821

[3] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[4] Breakthrough Fungemia Due to Candida glabrata During Posaconazole Prophylaxis in Hematology Patients Treated with Anidulafungin - Report of 5 Cases [J].

Krcmery, V. ;

Demitrovicova, A. ;

Kisac, P. .

JOURNAL OF CHEMOTHERAPY, 2011, 23 (05) :310-311

[5] Epidemiology and Outcome of Invasive Fungal Infection in Adult Hematopoietic Stem Cell Transplant Recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance Registry [J].

Neofytos, D. ;

Horn, D. ;

Anaissie, E. ;

Steinbach, W. ;

Olyaei, A. ;

Fishman, J. ;

Pfaller, M. ;

Chang, C. ;

Webster, K. ;

Marr, K. .

CLINICAL INFECTIOUS DISEASES, 2009, 48 (03) :265-273

[6] Invasive aspergillosis in patients with hematologic malignancies: incidence and description of 127 cases enrolled in a single institution prospective survey from 2004 to 2009 [J].

Nicolle, Marie-Christine ;

Benet, Thomas ;

Thiebaut, Anne ;

Bienvenu, Anne-Lise ;

Voirin, Nicolas ;

Duclos, Antoine ;

Sobh, Mohamad ;

Cannas, Giovanna ;

Thomas, Xavier ;

Nicolini, Frank-Emmanuel ;

De Monbrison, Frederique ;

Piens, Marie-Antoinette ;

Picot, Stephane ;

Michallet, Mauricette ;

Vanhems, Philippe .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (11) :1685-1691

[7]

Rojas R, 2012, MEDITERR J HEMATOL I, P4

[8] Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients [J].

Ruhnke, M. ;

Paiva, J. A. ;

Meersseman, W. ;

Pachl, J. ;

Grigoras, I. ;

Sganga, G. ;

Menichetti, F. ;

Montravers, P. ;

Auzinger, G. ;

Dimopoulos, G. ;

Borges Sa, M. ;

Miller, P. J. ;

Marcek, T. ;

Kantecki, M. .

CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (07) :680-687

[9]

Wetzstein Gene A, 2007, J Infect, V55, pe131, DOI 10.1016/j.jinf.2007.08.003

← 1 →